About Verge Genomics
Verge Genomics is a company based in San Francisco (United States) founded in 2015 by Jason Chen. Verge Genomics has raised $134.5 million across 4 funding rounds from investors including Lilly, WuXi AppTec and BlackRock. The company has 38 employees. Verge Genomics offers products and services including CONVERGE Platform and VRG50635. Verge Genomics operates in a competitive market with competitors including Biogen, Insitro, BridgeBio, ATAI and Denali Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 38
- Founders Jason Chen
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website vergegenomics.com
- Social LinkedIn X
- Legal Name Verge Analytics, Inc.
- Total Equity Funding$134.5M (USD)
in 4 rounds
- Latest Funding Round$98M (USD), Series B
Dec 2021
- InvestorsLilly
& 21 more
- Employee Count38
Products & Services of Verge Genomics
Verge Genomics offers a comprehensive portfolio of products and services, including CONVERGE Platform and VRG50635.
AI system for mapping disease causes and developing drug candidates.
Small molecule inhibitor targeting ALS and other neurological conditions.
Funding Insights of Verge Genomics
Verge Genomics has successfully raised a total of $134.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $98 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $134.5M
- Total Rounds 4
- Last Round Series B — $98M
- First Round $500,000
(Jul 2015)
- Investors Count 22
All 4 funding rounds of Verge Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $98M | Series B | – | BlackRock | |
| Jul 2018 | $32M | Series A | – | DFJ, WuXi AppTec | – |
| Nov 2015 | $4M | Seed | – | IA Ventures, Two Sigma Ventures | – |
| Jul 2015 | $500,000 | Seed | – | Y Combinator | – |
22 investors in total: 21 institutional and 1 angel.
Investors in Verge Genomics
Verge Genomics has secured backing from 22 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Lilly, WuXi AppTec and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate-backed venture capital is focused on the life science sector. | – | merckghifund.com | Kenilworth, United States | |
A venture capital fund focused on biotech for neurodegeneration. | – | alsinvestmentfund.com | Amsterdam, Netherlands | |
Venture capital firm focused on multiple sectors | – | taocap.com | Marlborough, United States | |
Early-stage startups are funded by Threshold VC firm. | – | threshold.vc | Palo Alto, United States | |
Venture capital firm focused on healthcare startups | – | lifeforcecap.com | San Francisco, United States | |
Tech startups are funded by S32, a venture capital entity. | – | s32.com | Sunnyvale, United States | |
US focused VC firm | – | dfj.com | Menlo Park, United States | |
Agent Capital is focused on healthcare venture capital investments. | – | agentcapital.com | Waltham, United States | |
Early-stage centric sector-agnostic VC firm investing in geographies such as the US | – | osfund.co | Chicago, United States | |
Seed and early-stage venture capital firm focusing on investments in technology and fintech companies | – | iaventures.com | New York, United States |
Investor details for Verge Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Verge Genomics
23 people are tracked at Verge Genomics (9 in leadership, 11 in board & advisors, 3 in team); the tracked headcount is 38.
| Name | Role | Group |
|---|---|---|
Jason Chen | Co-Founder | Leadership |
Ines Hoffman | Director & Head, Clinical Operations | Leadership |
Effie Bruzik | VP, Operations | Leadership |
Alice Zhang | CEO & Co-Founder | Leadership |
Jordan McGowan | Director Of Finance | Leadership |
Andrés E. Dulcey | Associate Director, Medicinal Chemistry | Leadership |
Victor Hanson-Smith | Distinguished Scientist, Head Of Computational Biology | Leadership |
Anil Tarachandani | VP, Head of Translational Medicine | Leadership |
Brian C. Shook | VP, Head of Medicinal Chemistry | Leadership |
Dave Madge | Director | Board & advisors |
Emily Melton | Director | Board & advisors |
Melanie Leitner | Director | Board & advisors |
Saira Ramasastry | Advisory Board Member | Board & advisors |
Steve Kanes | Director | Board & advisors |
Mario Saltarelli | Advisory Board Member | Board & advisors |
Andrew Allen | Director | Board & advisors |
Rita Balice-Gordon | Advisory Board Member | Board & advisors |
Matt Singer | Board Observer | Board & advisors |
Hani Goodarzi | Advisory Board Member | Board & advisors |
Al Sandrock | Director | Board & advisors |
3 more people are available in the full profile.
Complete people profiles for Verge Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Verge Genomics
3 dated milestones of Verge Genomics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Verge Genomics is founded.
- Funding First funding round of $500K.
- Funding Latest funding round, Series B, of $98.0M.
Competitors of Verge Genomics
Verge Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Insitro, BridgeBio, ATAI and Denali Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions |
Detailed competitors of Verge Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Verge Genomics
The website of Verge Genomics (vergegenomics.com) receives about 5.2K visits a month and ranks #3,696,665 among all websites worldwide, #4,744 in Biotechnology and Pharmaceuticals.
- Monthly visits5.2K
▲ 4.3% vs previous month
- Unique visitors2.2K
per month
- Global rank#3,696,665
among all websites
- Category rank#4,744
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.8
- Average visit22 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Verge Genomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| trc-canada.com | 33% | – | – | View details |
Latest news on Verge Genomics
Complete news archive for Verge Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Verge Genomics
10 companies that operate in the same segment as Verge Genomics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Verge Genomics
Verge Genomics was founded in 2015.
Verge Genomics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Verge Genomics is a funded company, having raised a total of $134.5M across 4 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Jul 2015.
Verge Genomics has 38 employees.
Verge Genomics was founded in 2015 in San Francisco, United States, within the biotechnology sector. Therapeutics for neurodegenerative diseases are developed through computational genomics, leveraging proprietary datasets from human samples. Disease-causing genes are mapped, and drugs are identified to target multiple genes concurrently. Conditions addressed include amyotrophic lateral sclerosis, Parkinsons disease, and frontotemporal dementia. Network algorithms are applied to genomic data to support this process.
Verge Genomics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Verge Genomics offers CONVERGE Platform and VRG50635.
Verge Genomics has 22 investors. Key investors include Lilly, WuXi AppTec, BlackRock, Merck Global Health Innovation Fund, and Vulcan Aerospace.
Verge Genomics operates through Verge Analytics, Inc..